Savant Capital’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.6M Sell
28,355
-1,837
-6% -$242K 0.01% 475
2026
Q1
$4.21M Buy
30,192
+3,108
+11% +$435K 0.02% 290
2025
Q4
$3.32M Buy
27,084
+1,589
+6% +$193K 0.02% 310
2025
Q3
$2.83M Buy
25,495
+860
+3% +$97.8K 0.02% 325
2025
Q2
$2.73M Buy
24,635
+3,249
+15% +$346K 0.02% 306
2025
Q1
$2.4M Sell
21,386
-6,535
-23% -$674K 0.02% 307
2024
Q4
$2.58M Buy
27,921
+558
+2% +$50.2K 0.02% 378
2024
Q3
$2.29M Buy
27,363
+4,077
+18% +$311K 0.02% 392
2024
Q2
$1.6M Sell
23,286
-1,747
-7% -$117K 0.02% 447
2024
Q1
$1.83M Sell
25,033
-717
-3% -$55.1K 0.02% 374
2023
Q4
$2.09M Sell
25,750
-875
-3% -$68.1K 0.03% 281
2023
Q3
$2M Sell
26,625
-151
-0.6% -$11.6K 0.03% 265
2023
Q2
$2.06M Buy
26,776
+356
+1% +$28.4K 0.03% 253
2023
Q1
$2.19M Buy
26,420
+1,203
+5% +$99.6K 0.04% 200
2022
Q4
$849K Buy
25,217
+16,275
+182% +$1.29M 0.02% 280
2022
Q3
$552K Sell
8,942
-226
-2% -$14.3K 0.02% 329
2022
Q2
$567K Buy
9,168
+861
+10% +$53.3K 0.02% 324
2022
Q1
$494K Buy
8,307
+481
+6% +$30.7K 0.02% 358
2021
Q4
$569K Buy
7,826
+2,058
+36% +$142K 0.02% 332
2021
Q3
$403K Sell
5,768
-327
-5% -$23K 0.01% 364
2021
Q2
$420K Sell
6,095
-92
-1% -$6.14K 0.02% 341
2021
Q1
$400K Buy
6,187
+93
+2% +$6K 0.02% 316
2020
Q4
$355K Sell
6,094
-691
-10% -$41.7K 0.02% 325
2020
Q3
$429K Sell
6,785
-373
-5% -$25.9K 0.03% 275
2020
Q2
$551K Buy
7,158
+321
+5% +$24.6K 0.04% 230
2020
Q1
$511K Buy
6,837
+1,009
+17% +$69.7K 0.05% 223
2019
Q4
$379K Buy
5,828
+113
+2% +$7.36K 0.05% 244
2019
Q3
$362K Sell
5,715
-140
-2% -$9.15K 0.05% 232
2019
Q2
$396K Sell
5,855
-59
-1% -$3.88K 0.06% 217
2019
Q1
$384K Buy
5,914
+227
+4% +$15.1K 0.07% 190
2018
Q4
$356K Sell
5,687
-446
-7% -$31.2K 0.07% 177
2018
Q3
$474K Sell
6,133
-31
-0.5% -$2.34K 0.09% 171
2018
Q2
$437K Sell
6,164
-41
-0.7% -$2.9K 0.09% 163
2018
Q1
$468K Buy
6,205
+108
+2% +$8.59K 0.1% 154
2017
Q4
$437K Buy
6,097
+260
+4% +$19.7K 0.09% 167
2017
Q3
$473K Buy
5,837
+47
+0.8% +$3.59K 0.11% 152
2017
Q2
$410K Buy
5,790
+194
+3% +$12.9K 0.1% 160
2017
Q1
$380K Sell
5,596
-2,019
-27% -$142K 0.09% 168
2016
Q4
$545K Sell
7,615
-935
-11% -$69.5K 0.15% 116
2016
Q3
$676K Sell
8,550
-304
-3% -$24.7K 0.19% 86
2016
Q2
$739K Sell
8,854
-26
-0.3% -$2.31K 0.21% 80
2016
Q1
$816K Sell
8,880
-600
-6% -$54.1K 0.25% 69
2015
Q4
$959K Buy
9,480
+2,330
+33% +$242K 0.3% 55
2015
Q3
$702K Buy
7,150
+481
+7% +$53.4K 0.25% 68
2015
Q2
$781K Sell
6,669
-344
-5% -$37.6K 0.26% 68
2015
Q1
$688K Buy
7,013
+389
+6% +$39.5K 0.24% 76
2014
Q4
$624K Buy
6,624
+380
+6% +$39.3K 0.24% 76
2014
Q3
$665K Hold
6,244
0.28% 61
2014
Q2
$518K Sell
6,244
-210
-3% -$16.3K 0.22% 81
2014
Q1
$457K Buy
6,454
+56
+0.9% +$4.39K 0.21% 80
2013
Q4
$480K Buy
6,398
+244
+4% +$17K 0.24% 70
2013
Q3
$387K Buy
6,154
+470
+8% +$28.1K 0.21% 77
2013
Q2
$291K Buy
+5,684
New +$296K 0.17% 98

Other funds holding GILD

Savant Capital's GILD Position: Q2 2026 in Review

Savant Capital reduced its Gilead Sciences (GILD) stake by 6.1% in Q2 2026, selling an estimated $242K and leaving 28,355 shares worth $3.6M. The position accounts for 0.01% of the portfolio, ranked #475.

Savant Capital first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. The position peaked at $4.21M in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Savant Capital held 28,355 shares of Gilead Sciences worth $3.6M as of Q2 2026.
  • Savant Capital sold 1,837 Gilead Sciences shares in Q2 2026, an estimated $242K.
  • Gilead Sciences made up 0.01% of Savant Capital's portfolio in Q2 2026, its #475 holding.
  • Savant Capital first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
  • Savant Capital's Gilead Sciences position peaked at $4.21M in Q1 2026.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Savant Capital's 13F filing for Q2 2026, filed 10 Aug 2026.